Cholangitis is inflammation of the bile ducts, but that short definition covers a surprisingly varied family of conditions. The term can refer to an acute bacterial infection triggered by a blocked bile duct, a slowly progressing autoimmune attack on microscopic ducts inside the liver, or a scarring process that narrows large bile ducts over years. What unites them is the anatomy involved: the branching network of tubes that carry bile from the liver to the intestine. When those tubes become inflamed, whether from infection, immune dysfunction, or obstruction, the consequences range from a treatable fever to end-stage liver disease requiring transplantation.
Acute Cholangitis and How It Starts
Acute cholangitis is the most immediately dangerous form. It begins when something blocks the flow of bile, most often a gallstone that has slipped into the common bile duct. Tumors, post-surgical strictures, and indwelling biliary stents can also create the obstruction. Once bile stagnates behind a blockage, bacteria from the intestine colonize it rapidly. The most frequently isolated organisms are Escherichia coli, Klebsiella species, and Enterococcus species, which together account for the large majority of positive blood and bile cultures in affected patients.1PubMed. Acute bacterial cholangitis2PubMed Central. Changing Patterns of Causative Pathogens over Time and Efficacy of Empirical Antibiotic Therapies in Acute Cholangitis with Bacteremia
Rising pressure inside the blocked duct is what turns a local infection into a systemic crisis. Research shows that as pressure climbs, the tight junctions sealing the tiny bile channels between liver cells begin to fail, allowing bacteria and bacterial toxins to leak directly into the bloodstream through the spaces between hepatocytes.3PubMed. Cholangio-venous reflux of biliary contents through paracellular pathways between hepatocytes in patients with acute cholangitis That reflux is how a bile duct problem can rapidly escalate into sepsis, organ failure, and death if drainage is not restored.
Recognizing Acute Cholangitis
For over a century, clinicians relied on a triad of symptoms: fever, jaundice, and right-upper-quadrant abdominal pain. That classic triad, however, turns out to be a poor screening tool. A systematic review covering more than 4,200 patients found that the triad’s overall sensitivity was only about 36%, meaning roughly two out of three people with acute cholangitis did not present with all three signs. Its specificity was high, around 93%, so when all three symptoms did appear together the diagnosis was usually correct, but waiting for the full triad would miss most cases.4PubMed. Diagnostic accuracy of Charcot’s triad: a systematic review Adding altered mental status and low blood pressure to the mix produces the five-feature cluster historically used to identify the most severe cases, but that expanded set captures fewer than 5% of patients.5PubMed Central. Evaluation of Charcot Triad, Reynolds Pentad, and Tokyo Guidelines for Diagnosis of Cholangitis Secondary to Choledocholithiasis Across Patient Age Groups
The Tokyo Guidelines, first published in 2007 and updated in 2013 and 2018, broadened the diagnostic criteria to include lab markers of inflammation, liver enzyme elevations, and imaging evidence of biliary dilatation. These criteria outperformed the classic triad. Analysis of large datasets confirmed that applying the updated Tokyo Guidelines yielded a significantly higher diagnostic rate than older criteria, and that patients classified at higher severity grades under these guidelines had correspondingly higher 30-day mortality, validating the grading system’s ability to stratify risk.6PubMed. Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholangitis (with videos) Even so, specificity remains a challenge in practice; one Japanese study found the guidelines’ specificity for suspected cholangitis was under 40%, a trade-off that reflects a deliberate design choice to favor catching more cases at the cost of some false positives.7PubMed. Accuracy of the Tokyo Guidelines for the diagnosis of acute cholangitis and cholecystitis taking into consideration the clinical practice pattern in Japan
Treatment Timing and Antibiotic Resistance
The cornerstone of treating acute cholangitis is draining the blocked bile duct, usually by threading a scope through the mouth and stomach into the duodenum and removing the obstruction or placing a stent. How quickly that procedure happens matters enormously. A meta-analysis pooling data from multiple studies found that performing drainage within 48 hours of admission, compared with delaying beyond 48 hours, roughly halved in-hospital mortality and shortened the hospital stay by about three and a half days.8PubMed Central. Timing of Performing Endoscopic Retrograde Cholangiopancreatography and Inpatient Mortality in Acute Cholangitis: A Systematic Review and Meta-Analysis A second meta-analysis confirmed the in-hospital mortality benefit of drainage within 24 or 48 hours and additionally showed that the 48-hour cutoff was associated with lower 30-day mortality as well.9PubMed Central. Impact of the Timing of Endoscopic Retrograde Cholangiopancreatography for the Treatment of Acute Cholangitis: A Meta-analysis and Systematic Review
Antibiotics are started immediately alongside plans for drainage, but choosing the right drug is growing more complicated. A study tracking bloodstream pathogens in cholangitis patients over many years found that the proportion of vancomycin-resistant enterococci climbed from zero to over 4% by the late 2010s, and carbapenem-resistant organisms began appearing as well.10PubMed Central. Changing Patterns of Causative Pathogens over Time and Efficacy of Empirical Antibiotic Therapies in Acute Cholangitis with Bacteremia Patients with biliary stents or prior procedures are at particular risk for multi-drug resistant bacteria. Research has shown that standard antibiotics frequently used as first-line therapy fail to cover the resistant organisms commonly found in these higher-risk patients, and broader-spectrum drugs are needed from the outset.11PLOS ONE. Risk Factors for Multi-Drug Resistant Pathogens and Failure of Empiric First-Line Therapy in Acute Cholangitis For patients with a history of healthcare-associated infection, prior biliary procedures, or severe disease, broader agents showed susceptibility rates above 90%, compared with roughly 75% for intermediate-spectrum options.12PubMed Central. Changing Patterns of Causative Pathogens over Time and Efficacy of Empirical Antibiotic Therapies in Acute Cholangitis with Bacteremia
Primary Biliary Cholangitis
Primary biliary cholangitis, or PBC, is an entirely different disease from the acute bacterial infection described above, despite sharing the word “cholangitis.” PBC is a chronic autoimmune condition in which the immune system attacks the small bile ducts inside the liver, gradually destroying them and eventually leading to scarring and, if untreated, cirrhosis.13PubMed Central. Autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis It predominantly affects middle-aged women and was formerly called primary biliary cirrhosis, a name changed because many patients are now diagnosed before cirrhosis ever develops.
The hallmark blood test is the anti-mitochondrial antibody, or AMA, which targets a specific component on the inner membranes of mitochondria. A meta-analysis of diagnostic accuracy found that AMA testing achieved a sensitivity of about 85% and a specificity around 98% for PBC, making it one of the most reliable autoimmune markers in clinical medicine.14PubMed. The accuracy of the anti-mitochondrial antibody and the M2 subtype test for diagnosis of primary biliary cirrhosis: a meta-analysis The specific antibody subtype targets the E2 component of the pyruvate dehydrogenase complex, which explains why the test is so disease-specific: that particular target is unique to PBC among liver diseases.15PubMed Central. Diagnostic value of anti-mitochondrial antibody in patients with primary biliary cholangitis: A systemic review and meta-analysis
The first-line treatment for PBC is ursodeoxycholic acid, a bile acid that slows disease progression in many patients. For those who do not respond adequately, obeticholic acid has been shown to improve bile flow. In a placebo-controlled trial, patients receiving obeticholic acid saw substantial drops in their alkaline phosphatase levels, a key marker of biliary damage, with reductions of over 100 units per liter more than what placebo achieved.16The New England Journal of Medicine. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis Imaging studies have shown how this drug works at a cellular level: it speeds up the secretion of bile acids from liver cells into the bile ducts, reducing the time potentially toxic bile acids spend sitting inside hepatocytes by roughly 30%.17Journal of Hepatology. Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis
Primary Sclerosing Cholangitis and Its Link to Bowel Disease
Primary sclerosing cholangitis, or PSC, involves chronic inflammation and scarring of both the large and small bile ducts, creating strictures that progressively choke off bile flow. Unlike PBC, PSC has no proven drug therapy that alters its course, and it affects men more often than women, typically appearing between ages 30 and 50. Up to 88% of people with PSC also have inflammatory bowel disease, most commonly ulcerative colitis.18Nature Reviews Disease Primers. Primary sclerosing cholangitis
The reason these two organs are so tightly linked is a subject of active investigation. The leading theory involves immune cells that are activated in the inflamed gut and then mistakenly migrate to the liver. The gut and the liver share certain molecular “address labels” on their blood vessel walls, so immune cells primed against intestinal targets can latch onto liver tissue as well, triggering inflammation there. Intriguingly, PSC sometimes develops after surgical removal of the colon, and inflammatory bowel disease sometimes appears for the first time after a liver transplant for PSC, suggesting that the misdirected immune traffic can flow in either direction.19Gut and Liver. Inflammatory Bowel Disease and Primary Sclerosing Cholangitis: A Review of the Phenotype and Associated Specific Features
Diagnosis of PSC relies heavily on imaging. Magnetic resonance imaging of the bile ducts achieves a sensitivity around 86% and specificity around 94% for detecting the characteristic pattern of strictures and dilations that looks like a beaded necklace on the scan.20PubMed. Primary sclerosing cholangitis: meta-analysis of diagnostic performance of MR cholangiopancreatography Follow-up imaging at 6- to 12-month intervals can push sensitivity even higher, above 90%, which matters because early PSC can be subtle on a single scan.21PubMed. Magnetic resonance cholangiopancreatography in the diagnosis of primary sclerosing cholangitis
Cancer Risk in Primary Sclerosing Cholangitis
One of the most feared complications of PSC is bile duct cancer, or cholangiocarcinoma. The chronic inflammation and scarring create an environment where malignant transformation can occur, and because the cancer often develops inside already-damaged ducts, it can be difficult to detect early. A prospective five-year surveillance study of PSC patients found that about 2% were diagnosed with cholangiocarcinoma during follow-up, and an additional 0.5% developed gallbladder cancer.22Journal of Hepatology. Prospective surveillance for cholangiocarcinoma in unselected individuals with primary sclerosing cholangitis Those numbers may sound modest, but over a lifetime of living with PSC, the cumulative risk is substantial. This is why most guidelines recommend regular screening with imaging and sometimes blood-based tumor markers, though no surveillance protocol has been conclusively shown to improve survival.
Liver Transplantation and Recurrence
When PSC or PBC progresses to end-stage liver disease, transplantation is the definitive treatment. Outcomes are generally favorable, with one- and five-year survival rates around 90% and 70 to 85%, respectively, for both conditions.23PubMed. Recurrence of primary sclerosing cholangitis, primary biliary cholangitis and auto-immune hepatitis after liver transplantation The catch is that both diseases can come back in the new liver. Recurrent PSC develops in roughly 8 to 27% of transplant recipients and recurrent PBC in about 11 to 42%.24PubMed. Recurrence of primary sclerosing cholangitis, primary biliary cholangitis and auto-immune hepatitis after liver transplantation
What drives recurrence in PSC is still debated. One study found that PSC recurrences after transplant occurred exclusively in patients who also had ulcerative colitis, and that the type of surgical bile duct reconstruction influenced the risk as well.25PubMed Central. Transplantation for Primary Sclerosing Cholangitis: Outcomes and Recurrence The hypothesis is that removing the colon may reduce the pool of gut-activated immune cells that migrate to the liver, which would be consistent with the gut-liver immune trafficking theory described above.26Journal of Hepatology. The relationship between primary sclerosing cholangitis and inflammatory bowel disease When PSC does recur, it tends to appear years later, with a median time to re-listing for transplant of about four and a half years.27PubMed Central. Transplantation for Primary Sclerosing Cholangitis: Outcomes and Recurrence
IgG4-Related Sclerosing Cholangitis
An important mimic of PSC is IgG4-related sclerosing cholangitis, a condition that can look almost identical on imaging and bloodwork but has a radically different trajectory. Where PSC has no proven medical therapy, IgG4-related sclerosing cholangitis typically responds dramatically to corticosteroids, with most patients seeing rapid improvement. Misdiagnosing one as the other can lead to unnecessary surgery or years of untreated autoimmune disease. The key distinguishing features include elevated serum IgG4 levels, involvement of other organs such as the pancreas, and the pattern of duct involvement on imaging.28PubMed Central. IgG4-Related Sclerosing Cholangitis and Primary Sclerosing Cholangitis Because the treatments and outcomes differ so profoundly, getting the distinction right early is one of the more consequential diagnostic challenges in hepatology.
Cholangitis in Children After Surgery for Biliary Atresia
In pediatric medicine, cholangitis most often appears in a very specific context: after the Kasai procedure, a surgery performed on infants born with biliary atresia, a condition in which the bile ducts outside the liver are absent or severely damaged. The Kasai operation connects a loop of intestine directly to the liver surface to allow bile to drain, but this new plumbing creates a permanent route for gut bacteria to ascend into the liver. Post-Kasai cholangitis is common and can be devastating, accelerating liver damage and bringing forward the need for transplant.
An international expert panel developed consensus definitions for this condition, deliberately setting a very low threshold for suspicion. Even a single clinical sign such as fever or a change in stool color, combined with one lab abnormality like rising bilirubin, is enough to trigger treatment.29PubMed Central. Cholangitis Definition and Treatment after Kasai Hepatoportoenterostomy for Biliary Atresia: A Delphi Process and International Expert Panel The reasoning is that waiting for a full clinical picture risks irreversible liver deterioration in an infant.
A meta-analysis of risk factors for post-Kasai cholangitis identified several predictors. Malnutrition roughly tripled the risk, low expression of vitamin D receptors nearly tripled it as well, and the presence of bile lakes in liver tissue more than doubled it. On the protective side, constructing an anti-reflux valve at the intestinal connection point and using high-dose steroids after surgery each reduced cholangitis episodes substantially.30PubMed Central. Risk factors for cholangitis after Kasai procedure in biliary atresia patients: a systematic review and meta-analysis The underlying causes of post-Kasai cholangitis remain incompletely understood, but are thought to include ascending bacterial infection from the intestinal conduit, reduced bile flow volume, and obstruction from scar tissue or kinking of the surgical loop.31Journal of Clinical and Experimental Hepatology. Post-Kasai Portoenterostomy Cholangitis: What Have We Learnt So Far?
AIDS Cholangiopathy
Before effective antiretroviral therapy became widespread, cholangitis was a recognized complication of advanced HIV infection. AIDS cholangiopathy involves inflammation and stricturing of the bile ducts caused not by gallstones or autoimmunity but by opportunistic infections that exploit a deeply weakened immune system. The most common culprit is Cryptosporidium parvum, a parasite that infects the bile duct lining, often alongside cytomegalovirus.32PubMed Central. AIDS-Associated Cryptosporidial and Cytomegalovirus Cholangiopathy In one early case series, abdominal pain was present in about three-quarters of patients, and intestinal cryptosporidiosis was found in 80%, suggesting that the biliary infection usually accompanies intestinal disease rather than occurring in isolation.33PubMed. AIDS-related cholangitis: diagnostic features and course in 15 patients Today, AIDS cholangiopathy is rare in settings where antiretroviral therapy is available, but it remains relevant in regions with limited access to HIV treatment and as a diagnostic consideration in any severely immunosuppressed patient presenting with unexplained biliary symptoms.
The Biliary Microbiome
Bile was long assumed to be sterile, but recent microbiome research has overturned that idea. Detailed sequencing of bile from patients with various cholestatic liver diseases has revealed a complex microbial community. The bile microbiome is dominated by bacteria from five main groups, with Proteobacteria, particularly Gammaproteobacteria, being the most abundant, followed by Firmicutes.34PubMed Central. Variation in Bile Microbiome by the Etiology of Cholestatic Liver Disease The composition varies depending on the underlying disease, and the bacterial community in bile differs from that of the gut, mouth, or blood, suggesting that the biliary tree harbors its own distinct ecosystem. Whether shifts in this microbiome cause disease, result from it, or both is an open question, but it adds a new dimension to understanding why some patients with biliary obstruction develop raging infections while others do not. The interplay between bacterial communities residing in the ducts and the immune environment of the liver is likely to be a productive area of research for years to come.